CIK 1974915
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 84.54% | 67 |
| Health Care Equipment & Supplies | 8.49% | 12 |
| Unclassified | 5.54% | 7 |
| Life Sciences Tools & Services | 0.85% | 2 |
| Health Care Providers & Services | 0.57% | 2 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines, Inc. | Health Care | 6.46% |
| 2 | BMRN | BIOMARIN PHARMACEUTICAL INC | Health Care | 5.65% |
| 3 | ABVX | Abivax S.A. | Health Care | 4.67% |
| 4 | NBIX | NEUROCRINE BIOSCIENCES INC | Health Care | 4.60% |
| 5 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | Health Care | 3.99% |
| 6 | ELVN | Enliven Therapeutics, Inc. | Health Care | 3.56% |
| 7 | RGEN | REPLIGEN CORP | Health Care | 3.05% |
| 8 | BCAX | Bicara Therapeutics Inc. | Health Care | 3.02% |
| 9 | NRIX | Nurix Therapeutics, Inc. | Health Care | 2.82% |
| 10 | APGE | Apogee Therapeutics, Inc. | Health Care | 2.59% |
83/90 names classified · sector 94.5% of weight · industry 94.5% · mkt cap 82.3%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 94.5% of the book is sector-classified (unclassified names shown, never dropped).
Only 25% of book weight classified — the grid is NOT representative of the whole book.
Classified: 25.4% of book weight (16/87 names) · unclassified 74.6%: RVMD, ABVX, ARWR, , ELVN, BCAX, NRIX, APGE, ASND, IMCR +61 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | RVMDREVOLUTION MEDICINES INC | 2,375,000 | $231M | 6.5% | ADD 705% |
| 2 | BMRNBIOMARIN PHARMACEUTICAL INC | 3,575,000 | $202M | 5.6% | ADD 19% |
| 3 | ABVXABIVAX SA | 1,500,000 | $167M | 4.7% | TRIM −21% |
| 4 | NBIXNEUROCRINE BIOSCIENCES INC | 1,250,000 | $165M | 4.6% | NEW |
| 5 | ARWRARROWHEAD PHARMACEUTICALS IN | 2,275,000 | $143M | 4.0% | ADD 153% |
| 6 | ELVNENLIVEN THERAPEUTICS INC | 3,250,000 | $127M | 3.6% | TRIM −15% |
| 7 | RGENREPLIGEN CORP | 925,000 | $109M | 3.0% | ADD 1014% |
| 8 | BCAXBICARA THERAPEUTICS INC | 5,425,000 | $108M | 3.0% | ADD 52% |
| 9 | NRIXNURIX THERAPEUTICS INC | 6,500,000 | $101M | 2.8% | ADD 39% |
| 10 | APGEAPOGEE THERAPEUTICS INC | 1,100,000 | $93M | 2.6% | ADD 100% |
| 11 | ASNDASCENDIS PHARMA A/S | 375,000 | $86M | 2.4% | ADD 114% |
| 12 | IMCRIMMUNOCORE HLDGS PLC | 2,766,868 | $83M | 2.3% | ADD 373% |
| 13 | TSHATAYSHA GENE THERAPIES INC | 18,000,000 | $80M | 2.2% | ADD 31% |
| 14 | DYNDYNE THERAPEUTICS INC | 4,000,000 | $73M | 2.0% | ADD 3233% |
| 15 | SNYSANOFI SA | 1,400,000 | $67M | 1.9% | NEW |
| 16 | BCRXBIOCRYST PHARMACEUTICALS INC | 7,025,000 | $67M | 1.9% | ADD 212% |
| 17 | SRRKSCHOLAR ROCK HLDG CORP | 1,324,422 | $65M | 1.8% | ADD 89% |
| 18 | IMTXIMMATICS N.V | 6,175,000 | $61M | 1.7% | HOLD |
| 19 | BMYBRISTOL-MYERS SQUIBB CO | 1,000,000 | $61M | 1.7% | ADD 300% |
| 20 | ALCALCON AG | 800,000 | $60M | 1.7% | TRIM −28% |
| 21 | GLUEMONTE ROSA THERAPEUTICS INC | 3,603,465 | $59M | 1.7% | ADD 365% |
| 22 | VERAVERA THERAPEUTICS INC | 1,368,159 | $55M | 1.5% | ADD 149% |
| 23 | TERNS PHARMACEUTICALS INC | 1,000,000 | $53M | 1.5% | TRIM −78% |
| 24 | GMEDGLOBUS MED INC | 610,520 | $53M | 1.5% | TRIM −52% |
| 25 | BSXBOSTON SCIENTIFIC CORP | 800,000 | $50M | 1.4% | NEW |
| 26 | NUVLNUVALENT INC | 481,715 | $49M | 1.4% | ADD 947% |
| 27 | COGTCOGENT BIOSCIENCES INC | 1,230,888 | $47M | 1.3% | NEW |
| 28 | ANROALTO NEUROSCIENCE INC | 2,064,075 | $46M | 1.3% | TRIM −17% |
| 29 | RAPPRAPPORT THERAPEUTICS INC | 1,436,229 | $45M | 1.3% | ADD 29% |
| 30 | IRONDISC MEDICINE INC | 700,000 | $45M | 1.3% | TRIM −5% |
| 31 | UTHRUnited Therapeutics Corp. | 75,000 | $44M | 1.2% | NEW |
| 32 | CLDXCELLDEX THERAPEUTICS INC NEW | 1,224,165 | $39M | 1.1% | ADD 5% |
| 33 | KALVISTA PHARMACEUTICALS INC | 1,850,000 | $37M | 1.0% | TRIM −2% |
| 34 | XENEXENON PHARMACEUTICALS INC | 639,900 | $37M | 1.0% | ADD 7% |
| 35 | SLDBSOLID BIOSCIENCES INC | 5,000,000 | $36M | 1.0% | TRIM −14% |
| 36 | DRUGBRIGHT MINDS BIOSCIENCES INC | 492,319 | $36M | 1.0% | NEW |
| 37 | PTGXPROTAGONIST THERAPEUTICS INC | 326,159 | $34M | 1.0% | NEW |
| 38 | DNLIDENALI THERAPEUTICS INC | 1,773,326 | $34M | 1.0% | ADD 281% |
| 39 | REGNREGENERON PHARMACEUTICALS | 40,000 | $31M | 0.9% | NEW |
| 40 | WATWATERS CORP | 100,000 | $30M | 0.8% | NEW |
| 41 | VKTXVIKING THERAPEUTICS INC | 914,147 | $30M | 0.8% | NEW |
| 42 | INSPINSPIRE MED SYS INC | 539,269 | $28M | 0.8% | NEW |
| 43 | CBIOCRESCENT BIOPHARMA INC. | 1,500,000 | $28M | 0.8% | HOLD |
| 44 | TRVITREVI THERAPEUTICS INC | 2,166,504 | $26M | 0.7% | NEW |
| 45 | LXEOLEXEO THERAPEUTICS INC | 4,475,000 | $26M | 0.7% | HOLD |
| 46 | SOLENO THERAPEUTICS INC | 730,000 | $24M | 0.7% | NEW |
| 47 | BBNXBETA BIONICS INC | 2,211,518 | $22M | 0.6% | ADD 269% |
| 48 | NKTRNEKTAR THERAPEUTICS | 285,000 | $21M | 0.6% | NEW |
| 49 | CYTKCYTOKINETICS INC | 300,000 | $20M | 0.6% | NEW |
| 50 | AZNASTRAZENECA PLC | 100,000 | $20M | 0.6% | NEW |
| 51 | WSTWEST PHARMACEUTICAL SVSC INC | 75,000 | $19M | 0.5% | NEW |
| 52 | GEHCGE HEALTHCARE TECHNOLOGIES I | 250,000 | $18M | 0.5% | NEW |
| 53 | SGPSPYGLASS PHARMA INC | 666,760 | $17M | 0.5% | NEW |
| 54 | ZBHZIMMER BIOMET HOLDINGS INC | 190,000 | $17M | 0.5% | ADD 27% |
| 55 | MDGLMADRIGAL PHARMACEUTICALS INC | 31,468 | $16M | 0.5% | NEW |
| 56 | WGSGENEDX HOLDINGS CORP | 250,000 | $16M | 0.4% | NEW |
| 57 | DMRADAMORA THERAPEUTICS INC | 600,000 | $16M | 0.4% | NEW |
| 58 | AGIOAGIOS PHARMACEUTICALS INC | 450,000 | $15M | 0.4% | ADD 38% |
| 59 | ENGENE HOLDINGS INC | 2,165,000 | $15M | 0.4% | ADD 105% |
| 60 | SVRASAVARA INC | 2,600,052 | $14M | 0.4% | ADD 62% |
| 61 | TARSTARSUS PHARMACEUTICALS INC | 200,000 | $14M | 0.4% | NEW |
| 62 | VYGRVOYAGER THERAPEUTICS INC | 3,002,936 | $12M | 0.3% | ADD 104% |
| 63 | PODDINSULET CORP | 50,601 | $11M | 0.3% | NEW |
| 64 | TECXTECTONIC THERAPEUTIC INC | 328,000 | $10M | 0.3% | HOLD |
| 65 | SRZNSURROZEN INC | 338,611 | $10M | 0.3% | NEW |
| 66 | ARVNARVINAS INC | 905,465 | $10M | 0.3% | NEW |
| 67 | MPLTMAPLIGHT THERAPEUTICS INC | 420,000 | $9M | 0.2% | ADD 9% |
| 68 | FULCFULCRUM THERAPEUTICS INC | 1,100,000 | $8M | 0.2% | ADD 16% |
| 69 | OKURONKURE THERAPEUTICS INC | 1,839,819 | $8M | 0.2% | ADD 190% |
| 70 | MYGNMYRIAD GENETICS INC | 1,648,000 | $7M | 0.2% | ADD 35% |
| 71 | OLMAOLEMA PHARMACEUTICALS INC | 428,551 | $6M | 0.2% | TRIM −74% |
| 72 | AVRANTERIS TECHNOLOGIES GLOBAL | 1,144,780 | $6M | 0.2% | NEW |
| 73 | QUREUNIQURE NV | 358,996 | $6M | 0.2% | NEW |
| 74 | CADLCANDEL THERAPEUTICS INC | 1,125,000 | $6M | 0.2% | NEW |
| 75 | PALIPALISADE BIO INC | 2,500,000 | $4M | 0.1% | NEW |
| 76 | VCYTVERACYTE INC | 130,687 | $4M | 0.1% | NEW |
| 77 | ZBIOZENAS BIOPHARMA INC | 200,000 | $4M | 0.1% | NEW |
| 78 | GERNGERON CORP | 2,540,000 | $4M | 0.1% | TRIM −78% |
| 79 | MNPRMONOPAR THERAPEUTICS INC | 65,418 | $4M | 0.1% | NEW |
| 80 | ZURAZURA BIO LTD | 511,000 | $3M | 0.1% | NEW |
| 81 | NVCRNOVOCURE LTD | 250,000 | $3M | 0.1% | TRIM −52% |
| 82 | NYXHNYXOAH S A | 868,661 | $3M | 0.1% | TRIM −22% |
| 83 | URGNUROGEN PHARMA LTD | 139,079 | $3M | 0.1% | NEW |
| 84 | PASGPASSAGE BIO INC | 305,000 | $2M | 0.1% | HOLD |
| 85 | TYRATYRA BIOSCIENCES INC | 54,000 | $2M | 0.1% | TRIM −98% |
| 86 | RGNXREGENXBIO INC | 108,525 | $909,440 | 0.0% | ADD 219% |
| 87 | TENXTENAX THERAPEUTICS INC | 53,439 | $854,490 | 0.0% | HOLD |
| 88 | MGNXMACROGENICS INC | 280,000 | $809,200 | 0.0% | HOLD |
| 89 | ABSIABSCI CORPORATION | 232,219 | $696,657 | 0.0% | NEW |
| 90 | APREAPREA THERAPEUTICS INC | 350,000 | $267,015 | 0.0% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| RVMDREVOLUTION MEDICINES INC | — | — | 1.2M | 630K | 295K | 2.4M | $231M |
| BMRNBIOMARIN PHARMACEUTICAL INC | 860K | — | 500K | 830K | 3.0M | 3.6M | $202M |
| ABVXABIVAX SA | — | — | — | 1.0M | 1.9M | 1.5M | $167M |
| NBIXNEUROCRINE BIOSCIENCES INC | — | — | 30K | — | — | 1.3M | $165M |
| ARWRARROWHEAD PHARMACEUTICALS IN | — | — | — | — | 900K | 2.3M | $143M |
| ELVNENLIVEN THERAPEUTICS INC | — | — | 250K | 1.2M | 3.8M | 3.3M | $127M |
| RGENREPLIGEN CORP | — | — | — | 400K | 83K | 925K | $109M |
| BCAXBICARA THERAPEUTICS INC | 710K | 2.8M | 5.0M | 5.1M | 3.6M | 5.4M | $108M |
| NRIXNURIX THERAPEUTICS INC | 485K | 1.1M | 2.0M | 3.5M | 4.7M | 6.5M | $101M |
| APGEAPOGEE THERAPEUTICS INC | — | — | — | 425K | 550K | 1.1M | $93M |
| ASNDASCENDIS PHARMA A/S | 520K | 150K | 200K | 600K | 175K | 375K | $86M |
| IMCRIMMUNOCORE HLDGS PLC | — | — | — | — | 585K | 2.8M | $83M |
| TSHATAYSHA GENE THERAPIES INC | — | — | 3.0M | 5.5M | 13.8M | 18.0M | $80M |
| DYNDYNE THERAPEUTICS INC | — | 1.8M | 728K | 2.8M | 120K | 4.0M | $73M |
| SNYSANOFI SA | 750K | — | — | — | — | 1.4M | $67M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
